Increasing to weekly adalimumab dosing leads to improved psoriasis outcomes-A retrospective single-centre review of real-world data.

Hussain, Amaani B; Havelin, Alison; Ball, Stephanie; Weatherhead, Sophie; Reynolds, Nick J; Hampton, Philip

Hussain, Amaani B; Havelin, Alison; Ball, Stephanie; Weatherhead, Sophie; Reynolds, Nick J; Hampton, Philip.

Affiliation

Hussain AB; Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Havelin A; Translational and Clinical Research Institute (Dermatology), Newcastle University, Newcastle upon Tyne, UK.
Ball S; Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Weatherhead S; Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Reynolds NJ; Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Hampton P; Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

J Eur Acad Dermatol Venereol ; 37(4): e527-e528, 2023 04.

Article in En | MEDLINE | ID: mdl-36178145

Subject(s)

Psoriasis; Humans; Adalimumab/therapeutic use; Retrospective Studies; Psoriasis/drug therapy; Antibodies, Monoclonal, Humanized; Treatment Outcome; Etanercept

Fulltext

XML

PubMed Links

Search on Google